Leren T P, Tonstad S, Gundersen K E, Bakken K S, Rødningen O K, Sundvold H, Ose L, Berg K
Department of Medical Genetics, Ullevål University Hospital, Norway.
J Intern Med. 1997 Mar;241(3):185-94. doi: 10.1046/j.1365-2796.1997.78119000.x.
To characterize mutations in the low density lipoprotein (LDL) receptor gene causing familial hypercholesterolaemia (FH) amongst Norwegian patients.
Molecular genetic analyses of the LDL receptor gene have been performed in patients with a clinical diagnosis of FH.
A total of 742 probands have been studied. Of these, 476 had a diagnosis of definite FH. The rest had a diagnosis of possible FH.
Twenty-three different mutations in the LDL receptor gene as well as the apolipoprotein B-3500 mutation have been found. Six of the mutations in the LDL receptor gene are novel mutations. A molecular genetic diagnosis was achieved in 295 of the probands with definite FH (62%) and in 317 probands total. Of the 317 probands, 3% carried the apolipoprotein B-3500 mutation. When family members were included, a total of 624 persons carried a mutation in the LDL receptor gene and 20 carried the apolipoprotein B-3500 mutation.
Approximately 5% of Norwegian FH patients have been provided with a molecular genetic diagnosis. Our data suggest that molecular diagnosis of FH in Norway is feasible and should be implemented in clinical medicine.
鉴定导致挪威患者家族性高胆固醇血症(FH)的低密度脂蛋白(LDL)受体基因突变。
对临床诊断为FH的患者进行LDL受体基因的分子遗传学分析。
共研究了742名先证者。其中,476人被诊断为确诊FH。其余被诊断为可能FH。
已发现LDL受体基因中的23种不同突变以及载脂蛋白B - 3500突变。LDL受体基因中的6种突变是新突变。在295名确诊FH的先证者(62%)以及总共317名先证者中实现了分子遗传学诊断。在317名先证者中,3%携带载脂蛋白B - 3500突变。当纳入家庭成员时,共有624人携带LDL受体基因突变,20人携带载脂蛋白B - 3500突变。
约5%的挪威FH患者已获得分子遗传学诊断。我们的数据表明,挪威FH的分子诊断是可行的,应在临床医学中实施。